Loading clinical trials...
Loading clinical trials...
Open Label, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of CYH33, an Oral PI3K Inhibitor in Combination With Olaparib, an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
Conditions
Interventions
CYH33
Locations
7
United States
Yale Cancer Center
New Haven, Connecticut, United States
UT Southwestern: Simmons Cancer Center
Dallas, Texas, United States
MD Anderson Cancer Center
Houston, Texas, United States
Scientia Cancer Centre
Sydney, New South Wales, Australia
Integrated Oncology Network PTY LTD
Brisbane, Queensland, Australia
Monash Cancer Centre
Melbourne, Victoria, Australia
Start Date
September 28, 2020
Primary Completion Date
February 15, 2023
Completion Date
February 15, 2023
Last Updated
March 21, 2024
NCT05468034
NCT04541381
NCT06144671
NCT06132828
NCT04570423
NCT06926283
Lead Sponsor
Haihe Biopharma Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions